Interview with John Dawson, Founder & CEO, Alliance Pharma plc
Today, Alliance Pharma Plc. represents a true pharmaceutical success story in the UK, distributing to 24 countries and moving towards GBP 50m annual turnover in just twelve years. If we…
Address: Avonbridge House, Bath Road, Chippenham, Wiltshire SN15 2BB, United Kingdom ,United Kingdom
Tel: +44 (0)1249 466966
Web: http://www.camb-labs.com/default.asp
Alliance is a speciality pharmaceutical group based in the United Kingdom and listed on AIM. The group was founded in 1998 and since then has established a strong track record of acquiring the rights to established niche products. Alliance now owns or licences over 50 prescription products. Pro forma annual sales now exceed £40m.
Alliance maintains strategic and controlling functions with a management team possessing considerable large pharmaceutical company experience. More labour and capital intensive functions are outsourced to maximise efficiency and profitability.
The core of Alliances’ activities are in the United Kingdom and the Republic of Ireland. The group also sells into approximately 20 other countries Worldwide, including via a joint venture into China.
Anti Infective, Cough, Cold & Flu
Cardiovascular
Central Nervous System
Dental
Dermatology
Diagnostics
Nutrition
Obstetrics & Gynaecology
Rheumatology
Toxicology
Oncology
Endocrinology
Today, Alliance Pharma Plc. represents a true pharmaceutical success story in the UK, distributing to 24 countries and moving towards GBP 50m annual turnover in just twelve years. If we…
First published in the November 2025 edition of DIA’s Global Forum, this piece by Jane Morrin O’Rourke, Naho Yamazaki, Becky Purvis (HRA) and Mandy Budwal-Jagait, Jason Wakelin-Smith and Kingyin Lee…
Originally published in the October 2025 edition of DIA’s Global Forum magazine, this article — authored by Mandy Budwal-Jagait, Kingyin Lee, Maria Urdaneta-Abate, Hedwig Ganguly, Rachel Mead, and Louisa Obillo…
As chief development officer of Moderna, Dr Melanie Ivarsson OBE spearheaded the rapid development of a COVID-19 vaccine that helped the world emerge from the pandemic. Now back in the…
Writing in the September 2025 edition of DIA’s Global Forum magazine, Janet Messer, Catherine Blewett, and Naho Yamazaki of the UK Health Research Authority (HRA) and Stephen Lam, Crina Cacou,…
Europe risks “slow death” in innovation unless it builds its own Silicon Valley, argues digital health investor Laurent van Lerberghe. With Macron pushing Anglo-French tech sovereignty, the UK and France…
The latest from UK pharma, including teething troubles and industry pushback for the country’s new life sciences strategy; Sanofi snapping up UK vaccines outfit Vicebio for USD 1.6 billion; and…
Writing in the July 2025 edition of DIA Global Forum, Samantha Holmes, Fiona Adshead, and Keith Moore of the Sustainable Healthcare Coalition explore how cross-sector partnerships are advancing environmental sustainability…
Lenny Shallcross, Executive Director of the World Dementia Council, reflects on the evolving global response to Alzheimer’s disease and dementia; from the slow but significant rollout of disease-modifying treatments to…
A roundup of the biggest UK pharma news, including the industry’s uncertain position after the UK-US trade accord; Haleon’s full takeover of its Chinese joint venture; AstraZeneca’s acquisition of Belgian…
UK Prime Minister Keir Starmer’s government continues its push to overhaul the country’s iconic National Health Service (NHS). After originally announcing plans to restructure NHS England, the body that manages…
Dr Carolyn H. Rogers, Rushikesh S. Dasoondi and Dr Michael A. Roberts from UK and European intellectual property law firm Reddie & Grose LLP examine the intersection of personalised medicine…
Fiona Carragher, Chief Policy and Research Officer at Alzheimer’s Society, delves into the organization’s mission to transform dementia care through innovation, advocacy, and global collaboration. Carragher addresses critical challenges, including…
See our Cookie Privacy Policy Here
